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higher antiproliferative activity (IC50 22.1, 19 and 15 lM against MCF7, SaOS-2 and K562, respec-
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SaOS-2 and K562 cells, respectively). Therefore, the present study demonstrates that ﬂuorine substi-
tuted 3,6-diaryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles would be a better prospective in the develop-
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Cancer remains to be the leading cause of death in humans sec-
ond only to cardiovascular diseases and more than 70% of all
cancer deaths occur in developing and under-developed coun-
tries (Fadeyi et al., 2008; Sherif and Rostom, 2006; Moorthy
et al., 2009). There is a continuous rise of deaths from various
cancers worldwide, with an estimated 12 million deaths in 2030
(WHO website). Despite the advancement in the knowledge of
biochemical processes associated with carcinogenesis, the suc-
cessful treatment of cancer remains a signiﬁcant challengeing Saud University.
cterization and anti cancer activity of some ﬂuorinated 3,6-diaryl-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.08.026
2 D. Chowrasia et al.because of the general toxicity associated with the clinical use
of traditional cancer chemotherapeutic agents. Hence, the de-
sign and development of new drugs for cancer therapeutics re-
mains to be an important and challenging task for medicinal
chemists worldwide.
The substituted-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole ring
represents an interesting class of hetero compounds with a
broad spectrum of pharmacological activities which include
antifungal (Karabasanagouda et al., 2007), anti-inﬂammatory
(Chawla et al., 2012), antiviral (Kritsanida et al., 2002), anal-
gesic (Chawla et al., 2012), anthelmintic (el-Khawass et al.,
1989), antibacterial (Holla et al., 1996) and antitumor agents
(Ibrahim, 2009). Of particular interest is the impressive anti-
cancer activity exhibited by this class of compounds. As a re-
sult, the literature is abundant with reports on the cytotoxic
potency of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles against var-
ious cancer cell lines (Holla et al., 2002; Bhat et al., 2009; Zhao
et al., 2012; Rashid et al., 2013; Sunil et al., 2010).
Fluorine-containing compounds have attracted much inter-
est since the introduction of ﬂuorine atoms or ﬂuoroalkyl moi-
eties to an organic compound can bring about remarkable
changes in the physical, chemical, and biological properties
(Wang et al., 2010). Fluoro compounds have also been tradi-
tionally associated with potent antitumor properties. Other
than the well established ﬂuoronucleosides such as 5-ﬂuoro
uracil, the ﬂuorine containing anticancer molecules include ﬂu-
tamide, an anti-androgen which was launched in 1983 for the
treatment of prostate cancer and ﬂuorinated anthracycline
antibiotics, steroids, Vitamin D3 analogs and ﬂuorine contain-
ing taxoids have been shown to be much more effective than
their parent analogs (Filler and Saha, 2009).
In view of the above mentioned ﬁndings and in continua-
tion of our interest in exploration of novel heterocyclic scaf-
folds for anticancer activity (Moorthy et al., 2009, 2010;
Patel et al., 2011), we report herein the synthesis and evalua-
tion of ﬂuorinated diaryl-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiaz-
oles as potential anticancer agents. Our design strategy was
to ﬁx up a penta ﬂuoro substitution in aryl ring (B) attached
to the thiadiazole scaffold and vary the substitution pattern
in the second aryl ring (A) attached to the triazole moiety as
shown in Fig. 1.
2. Materials and methods
2.1. Measurements
All commercial chemicals and solvents used are of reagent
grade and were used without further treatment unless other-
wise noted. 1H NMR spectra were recorded with a Bruker
Avance II 300 NMR spectrometer. Chemical shifts were re-
corded in parts per million (ppm) and were reported relative
to the TMS. Mass spectral data were recorded on an Applied
Biosystem Qtrap 3200 LC-MS/MS system in ESI mode. TheFigure 1 Design strategy of 6-(perﬂuorophenyl)-3-phenyl-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles.
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on Schimadzu IRPrestige-21 in KBr. Melting points of the
compounds were determined using a Veego digital melting
point apparatus and are reported uncorrected. The purity of
the compounds was conﬁrmed by thin layer chromatography
using Merck silica gel 60 F254 coated alumina plates.
2.2. Synthesis of 3,6-diphenyl-[1,2,4]triazolo[3,4-b][1,3,4]
thiadiazole derivatives (2a–2i)
An equimolar mixture (0.10 M) of 4-amino-5-substituted-3-
mercapto-(4H)-1,2,4-triazoles (3a,b) and aromatic acids in
phosphorus oxychloride (10 mL) was reﬂuxed for 5 h. The
reaction mixture was cooled to room temperature and then
gradually poured onto crushed ice with stirring. The mixture
was allowed to stand overnight and the solid separated out
was ﬁltered, treated with dilute sodium hydroxide solution
and washed thoroughly with cold water. The compound so ob-
tained was dried and crystallized from ethanol.
2.2.1. 3,6-Diphenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
(2a)
Yield 82 (%), m.p. 176–178 C, IR (KBr) m cm1: 3064 (Ar C–
H str), 2923 (methyl C–H str), 1517 (C‚N str), 1466 (C‚C
str), 971 (Ar–H bend); 1H NMR (400 MHz, DMSO-d6) d
(ppm): 7.49–7.71 (m, 6H of Ar–H), 8.06 (d, 2H of Ar–H,
J= 7.2), 8.33 (d, 2H of Ar–H, J= 7.65); MS (ESI): m/z
278.9 (M+H).
2.2.2. 6-(Perﬂuorophenyl)-3-phenyl-[1,2,4]triazolo[3,4-b]
[1,3,4]thiadiazole (2b)
Yield 73 (%), m.p. 207–209 C, IR (KBr) v (cm1): 3053 (Ar C–
H str), 2922 (methyl C–H str), 1511 (C‚N str), 1473 (C‚C
str), 1232 (Ar C–F str), 990 (Ar C–H bend); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 7.55–7.65 (m, 3H of Ar–H),
8.25(d, 2H of Ar–H, J= 7.8); MS (ESI): m/z 368.9 (M+H).
2.2.3. 3-(3-Methoxyphenyl)-6-(perﬂuorophenyl)-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazole (2c)
Yield 76 (%), m.p. 236–238 C, IR (KBr) m cm1: 3078 (Ar C–
H str), 2922 (methyl C–H str), 1513 (C‚N str), 1479 (C‚C
str), 1231 (C–O–C str Ar C–F str), 1178 (Ar C–F str), 991
(Ar C–H bend); 1H NMR (400 MHz, DMSO-d6) d (ppm):
3.84 (s, 3H of OCH3), 7.13 (d, 1H of Ar–H, J= 8.1), 7.52
(m, 1H of Ar–H, J= 8.1), 7.80 (t, 1H of Ar–H, J= 7.5);
MS (ESI): m/z 298.7 (M+H).
2.2.4. 3-(3,4-Dimethoxyphenyl)-6-(perﬂuorophenyl)-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazole (2d)
Yield 65 (%), m.p. 249–251 C, IR (KBr) m cm1: 2922 (Ar C–
H str), 2848 (methyl C–H str), 1490 (C‚N str), 1463 (C‚C
str), 1266 (C–O–C str), 1181 (Ar C–F str), 990 (Ar–H bend);
1H NMR (400 MHz, DMSO-d6) d (ppm): 3.82 (d, 6H of
OCH3), 7.18 (d, 1H of Ar–H, J= 7.8), 7.80 (d, 2H of Ar–H,
J= 9.6); MS (ESI): m/z 428.7 (M+H).
2.2.5. 6-(Perﬂuorophenyl)-3-(3,4,5-trimethoxyphenyl)-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazole (2e)
Yield 69 (%), m.p. 283–285 C, IR (KBr) m cm1: 2935 (Ar C–
H str), 2850 (methyl C–H str), 1485 (C‚N str), 1465 (C‚Ccterization and anti cancer activity of some ﬂuorinated 3,6-diaryl-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.08.026
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1H NMR (400 MHz, DMSO-d6) d (ppm): 3.76 (s, 3H of
OCH3), 3.86 (s, 6H of OCH3), 7.12 (s, 2H of Ar–H); MS
(ESI): m/z 458.6 (M+H).
2.2.6. 6-(Perﬂuorophenyl)-3-p-tolyl-[1,2,4]triazolo[3,4-b]
[1,3,4]thiadiazole (2f)
Yield 71 (%), m.p. 175–177 C, IR (KBr) m cm1: 2924 (Ar C–
H str), 2851 (methyl C–H str), 1485 (C‚N str), 1462 (C‚C
str), 1185 (Ar C–F str), 990 (Ar–H bend); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 2.40 (s, 3H of CH3), 7.43 (d,
2H of Ar–H, J= 7.5), 8.13 (d, 1H of Ar–H, J= 7.5); MS
(ESI): m/z 382.8 (M+H).
2.2.7. 3-(4-Nitrophenyl)-6-(perﬂuorophenyl)-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazole (2g)
Yield 46 (%), m.p. 212–214 C, IR (KBr) m cm1: 2921 (Ar C–
H str), 2851 (methyl C–H str), 1602 (nitro N‚O str), 1510
(C‚N str), 1492 (C‚C str), 1185(Ar C–F str), 990 (Ar–H
bend); 1H NMR (400 MHz, DMSO-d6) d (ppm): 7.36(d, 1H
of Ar–H, J= 8.1), 8.36 (d, 2H of Ar–H, J= 8.4); MS
(ESI): m/z 413 (M+H).
2.2.8. 4-(6-(Perﬂuorophenyl)-[1,2,4]triazolo[3,4-b][1,3, 4]
thiadiazol-3-yl)phenol (2h)
Yield 87 (%), m.p. 235–237 C, IR (KBr) m cm1: 2921 (Ar C–
H str), 2853 (methyl C–H str), 1513 (C‚N str), 1483 (C‚C
str), 1187 (Ar C–F str), 992.56 (Ar–H bend); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 7.41 (d, 1H of Ar–H,
J= 10.8), 8.27 (d, 2H of Ar–H, J= 31.5), MS (ESI): m/z
381 (M+H).
2.2.9. 6-(Perﬂuorophenyl)-3-(pyridin-4-yl)-[1,2,4]triazolo[3,
4-b][1,3,4]thiadiazole (2i)
Yield 68 (%), m.p. 164–166 C, IR (KBr) m cm1: 2925 (Ar C–
H str), 2853 (methyl C–H str), 1511 (C‚N str), 1479 (C‚C
str), 1184 (Ar C–F str), 988 (Ar–H bend); 1H NMR
(400 MHz, DMSO-d6) d (ppm): 8.28 (s, 2H of Ar–H), 8.850
(s, 2H of Ar–H); MS (ESI): m/z 396.7 (M+H).
2.3. Biological activity
2.3.1. Cell lines and culture
The human cancerous cell lines viz MCF-7 (breast cancer),
SaOS-2 (osteosarcoma), and K562 (myelogenous leukemia)
were obtained from cell repository-NCCS, Pune, India. The
cells were maintained in Eagle’s minimal essential medium
(MEM, Himedia), McCoy’s 5a medium (Himedia) and
RPMI-1640 (Himedia) respectively, and supplemented with
NaHCO3, sodium pyruvate, 10% fetal calf serum (Himedia),
and 1% penicillin and streptomycin. Cells were grown at
37 C, 5% CO2 in humidiﬁed air.
2.3.2. In vitro MTT assay for antiproliferative activity
The antiproliferative activities of the compounds were deter-
mined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide (MTT) assay (Sharma et al., 2010). MTT is a
quantitative colorimetric assay which is based on the phenom-
enon of enzymatic reduction of MTT dye. The assay provides
a direct relationship between the cell viability and colorPlease cite this article in press as: Chowrasia, D. et al., Synthesis, chara
[1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles. Arabian Journal of Chemistryformation (absorbance). The cells (MCF-7, SaOS-2 and
K562) were seeded at an initial density of 1 · 104 cells/100 lL
complete culture media in 96-well cultured plates and incu-
bated for 24 h at 37 C in humidiﬁed, 5% CO2 atmosphere.
Different concentrations of test compounds were added with
respective vehicle control (DMSO). The cell viability was
determined after 48 h of treatment, with the help of a micro-
plate reader (BIO RAD Model 680) at an absorbance of
540 nm. After 45 h of incubation, media were removed and
to each well 10 lL MTT (5 mg/mL of media without phenol
red and serum) was added and the plates were further incubated
for 3 h at 37 C. Supernatant from each well was carefully re-
moved and formazan crystals thus formed were solubilized by
mixing in 100 lL of DMSO. Subsequently for suspended cell
line K562 plate was centrifuged at 1500 rpm for 10 min after
addition of MTT and absorbance was recorded at 540 nm by
a microplate reader (BIO RAD Model 680).
The percentage cytotoxicity was calculated as per the for-
mula given below
%cell cytotoxicity ¼ ðOD controlOD treatedÞ  100ðOD controlÞ
The plot of % cytotoxicity versus sample concentration was
used to calculate the concentration lethal to 50% of the cells
(IC50).
3. Results and discussions
3.1. Chemistry
The strategy adopted for the synthesis of the target com-
pounds is depicted in Scheme 1. The intermediates 4-amino-
5-phenyl-4H-1,2,4-triazole-3-thiol (1a–1i) were prepared by
the fusion of the benzoic acids with thiocarbohydrazide
according to the reported procedure (Bhat et al., 2009). The
obtained 4-amino-5-phenyl-4H-1,2,4-triazole-3-thiols (1a–1i)
were then treated with pentaﬂuoro benzoic acids in the pres-
ence of phosphorous oxychloride to get the desired diaryl-
1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles (2a–2i). The structures
of all synthesized compounds were conﬁrmed on the basis of
IR, 1HNMR and mass spectral data.
3.2. Biological activity
The synthesized diaryl-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles
were tested for in vitro antiproliferative activity against
MCF7 (human breast cancer), SaOS-2 (osteosarcoma) and
K562 (myeloid leukemia) cells using MTT reduction assay.
The anticancer drug tamoxifen was used as reference standard.
All the nine compounds exhibited moderate antiproliferative
activity (<40 lM) against the three cancer cells used (Table 1).
Compound 2 was found to be the most potent compound in
the series with IC50 values of 22.1, 19 and 15 against MCF7,
SaOS-2 and K562 cells, respectively. In comparison to the
unsubstituted derivative 2a, compound 2b showed twofold
greater antiproliferative potency against SaOS-2 and K562
cells and a moderate improvement in MCF7 cell growth inhi-
bition clearly indicating that the ﬂuoro substitution beneﬁts
antiproliferative activity shown by the title compounds. In or-
der to improve the antiproliferative potency of compound 2b,
the aryl ring attached to triazole moiety was substituted withcterization and anti cancer activity of some ﬂuorinated 3,6-diaryl-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.08.026
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Scheme 1 Synthetic route for ﬂuorinated 3,6-diaryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles.
Table 1 Anti cancer activity of 3,6-diaryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles (2a–2i).
N
NN
N
S N
NN
N
S F
F
F
F
F
R
(2b -2g)(2a)
N
N
NN
N
S F
F
F
F
F
(2i)
Compound code R Cell growth inhibition (IC50 lM)
MCF-7 SaOS-2 K562
2a – 30.2 39 29.4
2b H 22.1 19 15
2c 3-OCH3 23 23.2 18.5
2d 3-OCH3, 4-OCH3 25.2 28.5 21.5
2f 3-OCH3, 4-OCH3, 5-OCH3 29.1 36.5 28
2f 4-CH3 28.8 36 26
2g 4-NO2 27.5 25 20
2h 4-OH 29.4 31 28.5
2i – 26.5 34.5 24.5
Tamoxifen _ 5.8 10.5 28.6
4 D. Chowrasia et al.electron releasing groups (2c–2f), electron withdrawing groups
(2g), Hydrogen bond donors and acceptors (2c–2f, 2h) and re-
placed with a heteroaryl pyridinyl ring (2i). In case of the
MCF7 cell growth inhibition, the structural manipulation at
the aryl ring resulted in a modest decrease in antiproliferative
activity with an exception of compound 2c which shows almost
comparable cell growth inhibition as that of compound 2b. A
similar phenomenon was also observed in the antiproliferative
activity against SaOS-2 and K562 cells. Overall, the ﬁndings
suggest that structural variation at the phenyl ring attached
to triazole core is not tolerated for the antiproliferative activity
exhibited by diaryl-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles.
4. Conclusion
A series of ﬂuorinated diaryl-1,2,4-triazolo-[3,4-b]-1,3,4-thi-
adiazoles was synthesized with an objective to study the effect
of ﬂuoro substitution in the aryl ring attached to thiadiazole
core and various substitutions in the aryl ring attached to
the triazole moiety on antitumor activity exhibited by thesePlease cite this article in press as: Chowrasia, D. et al., Synthesis, chara
[1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles. Arabian Journal of Chemistrycompounds. The synthesized compounds were tested in vitro
against human breast adenocarcinoma (MCF7), osteosarcoma
(SaOS-2) and myelogenous leukemia (K562) cell lines. The re-
sults of anticancer screening suggest that the penta ﬂuoro sub-
stitution in aryl ring A favors the antiproliferative activity
against all the three cancer cells whereas structural manipula-
tion at aryl ring B is detrimental to the antiproliferative
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